Selinexor + Ixazomib
Phase 1Withdrawn 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liposarcoma
Conditions
Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma, Ewing Sarcoma, Sarcoma
Trial Timeline
Nov 1, 2020 → Nov 24, 2020
NCT ID
NCT03880123About Selinexor + Ixazomib
Selinexor + Ixazomib is a phase 1 stage product being developed by Karyopharm Therapeutics for Liposarcoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03880123. Target conditions include Liposarcoma, Malignant Peripheral Nerve Sheath Tumors, Alveolar Soft Part Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03880123 | Phase 1 | Withdrawn |
Competing Products
12 competing products in Liposarcoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| efatutazone | Daiichi Sankyo | Phase 2 | 52 |
| Eribulin Mesylate | Eisai | Phase 1 | 33 |
| Trabectedin + Dexamethasone | Johnson & Johnson | Phase 2 | 52 |
| Yondelis + Yondelis + Dexamethasone + Dexamethasone | Johnson & Johnson | Phase 2 | 52 |
| HDM201 + LEE011 | Novartis | Phase 1 | 33 |
| pazopanib | Novartis | Phase 2 | 52 |
| PF-07220060 + Midazolam | Pfizer | Phase 2 | 51 |
| Sunitinib Malate (SU011248) | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| INCMGA00012 + Palbociclib | Incyte | Phase 2 | 49 |
| Selinexor + Placebo | Karyopharm Therapeutics | Phase 2/3 | 57 |